

Index

A

Acute necrotic collection (ANC)

- Atlanta classification, 6, 9
- CECT, 29–30
- percutaneous drainage, 36
- sterile necrosis, 34

Acute pancreatitis (AP)

- basal secretion, 126
- biliary pancreatitis, 206
- CECT findings, 198
- clinical diagnosis, 197
- definitions, 197
- early/late phase AP, 198
- endoscopic necrosectomy
 - composition of, 128
 - duration, 128
 - gastric feeding, 127
 - nasogastric (NG) feeding, 127
 - nasogastrojejunal (NGJ) tubing system, 127
 - nasojejunal (NJ) feeding, 127

enteral feeding, 127

fluid resuscitation (*see* Fluid resuscitation)

immunonutrition and probiotics, 129–130

interstitial edematous pancreatitis, 197

MAP, 199

mortality rate, 101

MSAP, 199

necrotizing pancreatitis, 197

NPO, 125–126

nutritional support, 124–125

pancreatic collections

- acute necrotic collections, 200
- acute peripancreatic fluid collections, 200
- pancreatic pseudocysts, 200
- prognostic measures, 200–201
- walled-off necrosis, 200

pancreatic secretion, 123–124

parenteral feeding, 130

pathophysiology of, 124

SAP, 199–200

severity (*see* Severity)

SIRS, 198

surgical management

- catastrophic abdomen, 201–203
- history, 201
- infected necrosis, 203–204

pancreatic abscess, 205

pancreatic fistulas, 205

pancreatic pseudocysts, 205

trypsin secretion, 126

tube feeding, 128–129

Acute peripancreatic fluid collection (APFC), 6, 9

Acute Physiology and Chronic Health Evaluation II (APACHE-II score), 47, 59, 89–90

Amphotericin B, 35

Antibiotics

CT-guided FNA, 119

extrapancreatic infections, 119

infected necrosis, 118–119

sterile necrosis

decontamination and probiotics, 118

experimental studies, 117

fungal infections, 118

human studies, 117–118

Aprotinin

antiprotease therapy, 102

peritoneal lavage delivery, 138

Atlanta classification

active intervention/other supportive measures, 48–49

CECT, 5–6

clinical practice

algorithmic approach, 12–13

features, 10, 12

laboratory-based assessment, 12–13

morphological evaluation, 13

mortality, 13

multicenter prospective study, 11–12

diagnosis, 4

IEP, 5, 7

infected necrosis

FNA, 8

pancreatic/peripancreatic tissue, 6–7

positive correlation, 5

local complication, 8

ANC, 6, 9

APFC, 6, 9

morphological features, 9–10

pancreatic pseudocysts, 9

walled-off necrosis, 6, 9

methodology, 3–4

mild acute pancreatitis, 11

moderately severe acute pancreatitis, 11

- Atlanta classification (*cont.*)
 morphological features, of severe disease, 48
 necrotizing pancreatitis, 5, 7
 objective evaluation, 3
 organ failure, 8, 47, 48
 phases, 5
 vs. revised classification, 3–4
 severe acute pancreatitis, 11
 systemic and local entities, 47, 48
 systemic complication, 10–11
 web-based consensus building approach, 47
- B**
 Bedside Index for Severity in Acute Pancreatitis (BISAP)
 score, 59, 60, 90–91
 Body mass index (BMI), 58
- C**
 Cambridge classification, 47
 CCK. *See* Cholecystokinin (CCK)
 CECT. *See* Contrast-enhanced computed tomography (CECT)
 Cholecystokinin (CCK), 124
 C1 inhibitor (C1INH), 24
 Clinical risk factors, 57–58
 Clinical scoring systems
 in acute pancreatitis, 58
 APACHE-II score, 59
 BISAP score, 59
 Glasgow score, 59
 POP score, 59
 Ranson score, 58
 SIRS score, 59–60
 Compensatory anti-inflammatory response syndrome (CARS), 5
 Computed tomography (CT)
 abdominal compartment syndrome, 82
 biliary complications, 80–81
 clinical assessment, 16
 diagnosis, 32–33
 extrapancreatic parenchymal complications, 79–80
 gastrointestinal complications, 81–82
 MDCT, 68
 necrosis infection, 77
 pancreatic necrosis, 76–77
 PCD, 214
 peripancreatic collections, 77–78
 renal function, 23
 vascular complications, 78–79
 Computed tomography-guided fine needle aspiration (CT FNA), 119
 Computed tomography severity index (CTSI), 63
 Continuous regional arterial infusions (CRAI), 138
 Contrast-enhanced computed tomography (CECT), 198
 diagnosis, 4, 30
 IEP, 5–6
 infected necrosis, 8
 local complication, 6, 9–10
 pancreatic/peripancreatic necrosis, 210–211
 PCD, 214
 phases, 5
 WOPN, 30
 C-reactive protein (CRP) level, 16
- D**
 Direct endoscopic necrosectomy, 37–38. *See also*
 Endoscopic necrosectomy (EN)
 Direct endoscopic necrosectomy (DEN)
 adverse events, 184–185
 history, 180
 infectious symptom, 184
 outcomes, 185
 paracolic gutter extension, 184
 percutaneous DEN, 184
 post-procedural care, 184
 preprocedural planning/sedation, 179–180
 puncture and access, 181–182
 SEMS, 182–183
 therapeutic upper endoscope, 183
 timing and indications, 180–181
 transmural tract, 182
 Disconnected duct syndrome (DDS)
 endoscopic and percutaneous treatment, 160, 162
 endoscopic management, 161
 external fistula, 159
 transmural stents, 162
- E**
 Early warning scores (EWS)
 abnormal scores, 19
 SIRS, 18–20
 therapeutic randomized trial, 20
 Endoscopic necrosectomy (EN)
 catheters, 38
 composition of, 128
 cystgastrostomy fistula, 38–39
 distal jejunal (DJ) feeding, 127
 duration, 128
 endoscopic drainage, 38
 endoscopic resolution, 38–39
 EUS-guided approach, 37
 gastric feeding, 127
 GEPARD study, 37–38
 nasogastric (NG) feeding, 127
 nasogastrojejunal (NGJ) tubing system, 127
 nasojejunal (NJ) feeding, 127
 PENGUIN trial, 38–39
 saline irrigation, 37
 Endoscopic retrograde cholangiopancreatography (ERCP), 156
 Endoscopic transmural necrosectomy (ETN)
 advantages, 223
 American multicenter study, 218–219
 complication, 220–222
 cystenterostomy, 216–217
 double pigtail stents, 222–223

- Dutch pancreatitis study group, 219
- factors, 220
- GEPARD study, 217–218
- limitations, 223
- multiple transmural entry, 218–219
- percutaneous catheters, 219–221
- WON, 216–218
- External fistula
 - conservative therapy, 159
 - cyanoacrylate injection, 161
 - DDS, 159
 - management, 159
 - multiple length stents, 159
 - nasojejunal feeding, 159
 - percutaneous and ransgastric drains, 159–160
 - use somatostatin analogues, 159
- F**
- Fine needle aspiration (FNA)
 - Atlanta classification, 8
 - infected pancreatic necrosis, 32–33
 - pancreatic/peripancreatic necrosis, 212
- Fluconazole, 35
- Fluid replacement, organ failure
 - admission hematocrit, 20
 - cohort study, 21
 - early hypovolemia, 21
 - early vs. late resuscitation group, 21
 - planning fluid therapy
 - crystalloid fluid replacement, 21–22
 - fatal outcomes, 22
 - gastric tonometry, 22
 - IFABP, 22
 - Ringer's lactate, 21–22
- Fluid resuscitation
 - animal studies, 103–105
 - clinical recommendations, 108
 - future aspects, 108–109
 - human studies
 - dextran, 106
 - pH-balanced solution, 107
 - rapid hemodilution, 107
 - retrospective study, 105–106
 - risk factors, 107
 - pancreatic microcirculation, 102–103
- Fluid sequestration, 96
- G**
- Gallstone pancreatitis
 - endoscopic retrograde cholangiopancreatography
 - Asian and non-Asian patients, 174
 - CBD stone, 174–175
 - clinical effectiveness and safety, 173
 - direct cholangiography, 171
 - direct cholangioscopy, 171–172
 - endoscopic imaging, 171
 - ES, 172–173
 - with ES, 171
 - intraductal ultrasonography, 171–172
 - endoscopic ultrasound, 170–171
 - Gastric tonometry, 22
 - Glasgow-Imrie score, 90
- H**
- Harmless acute pancreatitis score (HAPS), 60, 91–92
- I**
- Infected pancreatic necrosis (IPN)
 - ANC, 29–30
 - clinical management
 - aggressive intravenous fluid resuscitation, 33
 - algorithmic approach, 33–34
 - amphotericin B, 35
 - conservative therapy, 35–36
 - endoscopic necrosectomy, 37–39
 - fluconazole, 35
 - minimally invasive retroperitoneal necrosectomy, 36–37
 - paradigm shift, 34
 - percutaneous drainage, 36
 - prophylactic antibiotics, 35
 - step-up approach, 39–40
 - surgical therapy, 35–36
 - diagnosis
 - clinical study, 32
 - CT imaging, 32–33
 - development, 31–32
 - FNA, 32–33
 - gastroenterology guidelines, 32
 - gram-negative bacteria, 32
 - imaging, 30–32
 - diagnosis of, 115–116
 - epidemiology, 116
 - nonviable pancreatic tissue, 29
 - WOPN, 30
- Intercellular cell adhesion molecule 1 (ICAM-1), 134
- Interleukins, 23–24
- Interstitial edematous pancreatitis (IEP), 5, 7, 197
- Intestinal fatty acid-binding protein (IFABP), 22
- J**
- Japanese severity score, 93–94
- K**
- Kallikrein-Kinin system, 135
- L**
- Laboratory markers, 60–61
- Lexipafant, 24
- Logistic organ dysfunction score (LODS), 16

M

- Magnetic resonance cholangiopancreatography (MRCP), 156
- Magnetic resonance imaging (MRI), 68
 - diagnosis, 4
 - local complication, 9
 - pancreatic/peripancreatic necrosis, 211
 - T1-weighted image, 30–31
 - T2-weighted image, 31–32
- Marseilles classification, 47
- Marshall scoring system, 8, 15–16
- Mild acute pancreatitis (MAP), 199
- Minimally invasive retroperitoneal necrosectomy, 36–37
- Moderately severe acute pancreatitis (MSAP), 199
- Modified early warning scores (MEWS). *See* Early warning scores (EWS)
- Multidetector computed tomography (MDCT)
 - computed tomography, 68
 - magnetic resonance imaging, 68
 - ultrasound, 68

N

- Necrosectomy, 213
- Necrotizing pancreatitis (NP)
 - Atlanta classification, 5, 7
 - disconnected pancreatic duct, 225–226
 - enteral nutrition, 226
- ETN
 - advantages, 223
 - American multicenter study, 218–219
 - complication, 220–222
 - cystenterostomy, 216–217
 - double pigtail stents, 222–223
 - Dutch pancreatitis study group, 219
 - factors, 220
 - GEPARD study, 217–218
 - limitations, 223
 - multiple transmural entry, 218–219
 - percutaneous catheters, 219–221
 - WON, 216–218
- future aspects, 226–227
- indication, 212
- infected/sterile necrosis, 198
- intervention, 212
- laparoscopic debridement, 223–224
- management strategies, 189
- minimally invasive approach, necrosectomy, 213
- minimally invasive retroperitoneal approach, 224–225
- minimally invasive techniques, 190
- open surgical debridement, 209–210
- pancreatic/peripancreatic necrosis
 - CECT, 210–211
 - FNA, 212
 - MRI, 211
 - peak incidence, 211–212
- PCD
 - CECT, 214
 - clinical practice, 215–216
 - CT angiogram, 214

- sinus tract endoscopy, 214–215
 - treatment modality, 214–215
 - VARD, 214–215
 - retroperitoneoscopic techniques
 - sinus tract endoscopy, 190–191
 - VARD, 191–193
 - revised Atlanta classification, 209–210
 - step-up approach, 225
 - walled-off collection, 216–217, 226
- Net reclassification improvement” (NRI), 50, 51

O

- Obesity, 58
- Organ failure
 - anti-inflammatory treatment
 - CIINH, 24
 - complex physiological disturbances, 24
 - interleukins, 23–24
 - lexipafant, 24
 - Atlanta classification, 8
 - clinical assessment
 - APACHE-II scores, 16
 - Atlanta definition, 15–16
 - CRP level, 16
 - degrees of dysfunction, 16
 - LODS, 16
 - single threshold, 15
 - computed tomography, 23
 - diagnosis, 15–16
 - early management, 20
 - early organ failure
 - detection, 16–17
 - fatal outcomes, 17
 - multicentre study, 17
 - prediction, 16–17
 - SIRS, 17–18
 - substantial adverse prognostic factor, 17
 - fluid replacement
 - admission hematocrit, 20
 - cohort study, 21
 - early hypovolemia, 21
 - early vs. late resuscitation group, 21
 - fluid therapy, 21–22
 - pain relief, 22–23
 - persistent organ failure, 19
 - physiological response
 - abnormal scores, 19
 - SIRS, 18–20
 - therapeutic randomized trial, 20
 - pro-inflammatory pathway, 23

P

- Pancreatic duct leaks
 - adverse events, 162–163
 - ascites, 155
 - clinical features
 - clinical manifestations, 151–152
 - pancreatic fluid collection, 152

- pseudocyst formation, 152
 - signs and symptoms, 152
 - size, 152
 - walled-off pancreatic necrosis, 153
 - diagnosis, 153–154
 - disconnected duct syndrome, 160–162
 - epidemiology, 151
 - external fistula
 - conservative therapy, 159
 - cyanoacrylate injection, 161
 - DDS, 159
 - management, 159
 - multiple length stents, 159
 - nasojejunal feeding, 159
 - percutaneous and ransgastric drains, 159–160
 - use somatostatin analogues, 159
 - management, 154–155
 - pancreatic fistula and trauma, 158
 - pseudocyst
 - characteristics of, 155
 - clinical history, 156
 - complex cysts, 156
 - cyst-enteric/cyst-gastric anastomoses, 156
 - endoscopic/interventional radiology drainage, 156
 - ERCP/MRCP, 156
 - EUS and non-EUS-guided transmural drainage, 156, 157
 - high-quality cross-sectional imaging, 155
 - outcomes, 157
 - WOPN, 156
 - Pancreatic microcirculation, 102–103
 - Pancreatic/peripancreatic necrosis
 - CECT, 210–211
 - FNA, 212
 - MRI, 211
 - peak incidence, 211–212
 - Pancreatic pseudocysts, 9
 - Pancreatitis outcome prediction (POP) score, 59, 92
 - Panc 3 score, 92–93
 - Percutaneous catheter drainage (PCD)
 - CECT, 214
 - clinical practice, 215–216
 - CT angiogram, 214
 - sinus tract endoscopy, 214–215
 - treatment modality, 214–215
 - VARD, 214–215
 - Percutaneous drainage, 36
 - Pharmacologic therapy
 - objectives, 133, 134
 - pathophysiology
 - acinar cell injury, 134
 - bacterial translocation, 134
 - blocking normal secretory activity, 133
 - complement system, 134, 135
 - immune system, 134
 - Kallikrein-Kinin system, 135
 - local and systemic inflammatory mechanisms, 134–135
 - mechanisms of action, 133, 135
 - pro and anti-inflammatory cytokines, 134
 - systemic inflammatory response syndrome, 134
 - VCAM-1 and ICAM-1 expression, 134
 - pharmacological agents, 136
 - anti-inflammatory agents, 140
 - antioxidant agents, 139–140
 - anti-secretory agents, 136–137
 - immunomodulators, 139
 - PEP, 140–142
 - protease inhibitors, 137–139
 - therapeutic development, 142–143
 - Post-ERCP pancreatitis (PEP)
 - antioxidant therapy, 142
 - anti-secretory agents, 141
 - clinical trials, 141
 - immunomodulators, 142
 - incidence, 141
 - non-steroidal anti-inflammatory medications, 142
 - protease inhibitors, 141–142
 - Protease inhibitors
 - aprotinin, 138
 - gabexate mesilate, 138–139
 - nafomostat, 138
 - Pseudocyst
 - characteristics of, 155
 - clinical history, 156
 - complex cysts, 156
 - cyst-enteric/cyst-gastric anastomoses, 156
 - endoscopic/interventional radiology drainage, 156
 - ERCP/MRCP, 156
 - EUS and non-EUS-guided transmural drainage, 156, 157
 - high-quality cross-sectional imaging, 155
 - outcomes, 157
 - WOPN, 156
- R**
- Radiographic scores, 62–63
 - Radiologic scoring systems
 - Balthazar grade, 69–70
 - CT severity index, 70–71
 - EPIC score, 73
 - modified CT severity index, 71–72
 - MOP score, 71
 - pancreatic size index, 70
 - retroperitoneal extension grade, 72
 - Schröder index, 68–69
 - severity prediction, 73–75
 - Ranson score, 88–89
 - Routine laboratory tests, 95–96
- S**
- Secretin, 124
 - Self-expandable metal stents (SEMS), 37, 182–183
 - Serum hematocrit, 61
 - Severe Acute Pancreatitis (SAP), 199–200
 - Severity
 - classification of
 - Atlanta classification (*see* Atlanta classification)
 - Cambridge classification, 47
 - comparative studies, 50–51

Severity (cont.)

- determinants, 49–50
- Marseilles classification, 47
- optimal number, 50
- complications, 45, 46
- descriptive definition, 45
- dimensions of, 46
- extensional definition, 46
- intensional definition, 45
- nominal definition, 45

Sterile pancreatic necrosis. *See* Infected pancreatic necrosis

Systemic inflammatory response syndrome (SIRS),

- 59–60, 91, 198
- early organ failure, 17–18
- infected necrosis, 32–33
- physiological response, 19–20
- SIRS score system, 5
- transient/persistent organ failure, 5

T

- Toll-like receptors (TLRs), 134
- Transabdominal ultrasonography
 - diagnosis, 4
 - local complication, 9

U

- Ultrasound
 - MDCT, 68
 - transabdominal ultrasonography
 - diagnosis, 4
 - local complication, 9

V

- Vascular cell adhesion molecule
 - 1 (VCAM-1), 134
- Video-assisted retroperitoneal debridement (VARD),
 - 36–37, 184
 - necrotizing pancreatitis, 191–193
 - PCD, 214

W

- Walled-off necrosis (WON), 6, 9
- Walled-off pancreatic necrosis (WOPN),
 - 153, 156
 - CECT, 30–32
 - endoscopic necrosectomy, 37–38
 - percutaneous drainage, 36
 - sterile asymptomatic, 34
 - surgical therapy, 35